1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
ST PHARM CO., LTD.

ST PHARM CO., LTD.

KKRX:237690
89,900.00
KRW
+100.00
(+0.11%)
3,698.48EPS
35.71P/E
2.75TMarket Cap
Oct 29Next Earn
ST PHARM CO., LTD.
KRX:237690
(Korea Stock Exchange)

Recent

price

89,900.00

P/E

ratio

35.71

div

yld

- -

ROIC.AI

2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
KRW
11,514.68
15,926.88
12,593.98
10,915.92
5,241.3
4,997.87
6,651.33
8,851.91
13,255.59
15,151.09
14,037.83
16,321.17
18,629.26
Revenue per Share
652
2,906
3,861
2,422
-497
-993
-651
177
957
1,041
1,780
2,706
3,701.99
Basic EPS, GAAP
-1,982.47
1,548.6
2,183.95
1,437.27
-887.24
-1,973.83
-2,056.85
-2,386.01
-2,851.46
-2,240.54
1,344.91
-1,638.4
3,716.7
Free Cash Flow per Basic Share
136.33
120.88
185.13
497.47
500.22
499.91
- -
- -
500
499.97
482.25
495.84
- -
Dividend per Share
3,093.42
5,998.26
16,946.43
18,818.76
17,772.78
16,124.69
15,830.19
17,171.46
17,950.76
20,445.26
24,965.77
28,478.35
30,207.57
Book Value per Share
3,048.56
5,939.16
16,888.02
18,753.86
17,697.35
15,636.85
15,294.42
16,500.56
17,287.3
19,729.5
24,145.44
27,662.26
29,379.86
Tangible Book Value per Share
8
9
16
19
19
19
19
19
19
19
20
20
21
Basic Weighted Avg Shares
96,540
138,052
200,362
202,800
97,738
93,257
124,109
165,642
249,322
284,992
273,751
331,681
386,456
Sales/Revenue/Turnover
10.08
24.97
38.72
30.49
-16.01
-28.63
-15.16
3.37
7.16
11.76
10.12
16.56
18.33
Operating Margin (%)
4,304
6,161
10,785
11,568
9,230
11,185
14,068
14,414
17,600
23,027
25,582
29,881
33,799
Depreciation Expense
5,466
25,189
61,426
44,997
-9,268
-18,529
-12,147
3,312
18,000
19,581
34,712
54,992
76,796
Net Income, GAAP
42.33
29.25
23.69
24.05
- -
- -
- -
- -
8.95
24.97
24.06
7.09
10.71
Effective Tax Rate (%)
5.66
18.25
30.66
22.19
-9.48
-19.87
-9.79
2
7.22
6.87
12.68
16.58
19.87
Profit Margin (%)
-25,676
-12,448
173,402
196,567
157,344
127,925
217,003
191,567
84,010
264,634
196,797
207,916
250,899
Working Capital
176
10,156
137
117
98
15,551
126,033
91,930
19,188
161,832
44,767
929
703
LT Debt
57,180
110,874
313,245
351,083
331,569
303,209
296,753
326,033
341,103
386,906
502,991
593,004
629,071
Total Equity
- -
19.28
24.12
13.7
- -
- -
- -
- -
3.56
4.74
3.47
7.81
9.49
Return on Invested Capital (%)
- -
23.26
26.72
13.56
- -
- -
- -
- -
4.64
4.97
7.14
9.15
11.61
Return on Capital (%)
- -
29.98
28.97
13.55
-2.72
-5.86
-4.08
1.07
5.45
5.42
7.82
10.03
13.59
Return on Common Equity (%)

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
77,785
73,616
74,112
LT Borrowings
- -
- -
- -
LT Finance Leases
929
715
703
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
2,483,935
3,013,229
2,754,833

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
372,668
445,206
447,121
Cash, Cash Equivalents & STI
90,990
199,090
170,440
Accounts Receivable, Net
96,661
37,519
47,271
Inventories
169,471
194,524
196,386
Total Current Liabilities
164,752
214,424
196,222
Payables & Accruals
- -
- -
- -
ST Debt
77,785
73,616
74,112
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.42%
15.16%
17.9%
Free Cash Flow
-27.36%
-74.83%
-226.95%
Net Income, GAAP
52.27%
92.13%
58.42%
Sales/Revenue/Turnover
13.86%
23.1%
21.16%
Total Cash Common Dividend
- -
- -
7.15%

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51,721
44,592
61,703
115,735
273,751
2025
52,420
68,251
81,910
129,100
331,681
2026
66,961
108,484
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
331
53
750
637.78
1,780
2025
52
269
849
1,495.11
2,706
2026
725
635
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
482.25
2025
- -
- -
- -
- -
495.84
2026
- -
- -
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
ST Pharm Co., Ltd. (237690.KQ) is a South Korea-based contract development and manufacturing organization (CDMO) that provides custom manufacturing services for active pharmaceutical ingredients (APIs) and intermediates, specializing in oligonucleotides, RNA-based therapeutics, and small molecule APIs for pharmaceutical and biotech companies worldwide; its core offerings include small molecule and generic APIs such as those for viral infections, MRI contrast agents, tuberculosis, and anti-infectives; oligonucleotide-based products encompassing siRNA/microRNA, antisense oligonucleotides, aptamers, decoys, and novel oligos; monomers from nucleosides to phosphoramidites; mRNA for vaccines and therapeutics with proprietary technologies like SmartCap capping platform and STLNP lipid nanoparticles; and pre-clinical bioanalytical R&D solutions through subsidiary AnaPath Research & Service. The company operates cGMP manufacturing, quality control, and R&D facilities at its Banwol campus in Ansan-si, Gyeonggi-do, with headquarters in Siheung-si, Gyeonggi-do, and a Seoul office handling marketing, sales, and regulatory affairs, alongside global locations in Switzerland, Spain, and the United States. Founded in 1983 as Samchully Pharmaceutical Company Ltd., ST Pharm rebranded to focus on advanced gene therapy CDMO capabilities, supporting over 40 global projects with capacities of 6.4 mole for oligo and 1.0 kg/year for mRNA; recent developments include a January 2025 partnership with Evonik to integrate customized nucleic acids with lipid nanoparticle services for faster nucleic acid therapeutic development, completion of Phase 2a patient enrollment for antiviral candidate STP0404 (Pirmitegravir) in May 2025, publication of next-generation mRNA vaccine research in May 2025, trademark registration for SmartCap and STLNP platforms in March 2025, release of its first sustainability report in June 2025, and participation in TIDES USA 2025 to expand in the North American RNA market.